DAVID BENJAMIN SOLL
Medical Practice in Philadelphia, PA

5006123, Apr 9, 1991

Sep 7, 1989

7/404146

David B. Soll - Philadelphia PA
Stephen J. Failla - Chester NJ

A61F 900

606166

A marking device is provided for marking the sclera and/or limbus of a patient's eye to standardize and define incision location and suture placement prior to cataract removal, and to aid in the intraoperative control of astigmatism. The device comprises a generally arcuate body member having opposed major surfaces with a plurality of projections extending from one of the major surfaces. The body member has an inferior arc and a superior arc with the inferior arc having a smaller radius than the superior arc. The projections are radially aligned, extending from the major surface and are adapted to be inked and to transfer ink marks to the sclera and/or limbal area of an eye. The ink marks represent the locations where incisions and sutures are to be placed.

5166048, Nov 24, 1992

Aug 14, 1991

7/749463

David B. Soll - Philadelphia PA
Sol E. Harrison - Huntingdon Valley PA

A01N 102

435 1

The cells of the coverings and linings of internal human and animal tissues, organs and body cavities subject to trauma, such as surgery, may be protected against exfoliation or destruction by the topical application or injection of effective amounts of chondroitin sulfate prior to or during the trauma. Preferably, the chondroitin sulfate is used in physiological solutions in concentrations of about 40 to 55 weight percent, and may be used as a surgical irrigating solution. Intraarticular injection of such chondroitin sulfate solutions into human and animal joints having degenerative joint conditions protects the joint cells, reduces aseptic inflammation and/or prevents further degeneration of cartilage tissue. Solutions for preserving human and animal cells and tissues in vitro for later in vivo use have extended storage life when chondroitin sulfate is added to such storage solutions in effective amounts such as about 1 to 20 weight percent of the storage solution.

5498606, Mar 12, 1996

Aug 19, 1993

8/109206

David B. Soll - Philadelphia PA
Sol E. Harrison - Huntingdon Valley PA

A61K 3170

514 54

The cells of the coverings and linings of internal human and animal tissues, organs and body cavities subject to trauma, such as surgery, may be protected against exfoliation or destruction by the topical application or injection of effective amounts of chondroitin sulfate prior to or during the trauma. Preferably, the chondroitin sulfate is used in physiological solutions in concentrations of about 40 to 55 weight percent, and may be used as a surgical irrigating solution. Intraarticular injection of such chondroitin sulfate solutions into human and animal joints having degenerative joint conditions protects the joint cells, reduces aseptic inflammation and/or prevents further degeneration of cartilage tissue. Solutions for preserving human and animal cells and tissues in vitro for later in vivo use have extended storage life when chondroitin sulfate is added to such storage solutions in effective amounts such as about 1 to 20 weight percent of the storage solution.

4971955, Nov 20, 1990

Mar 2, 1988

7/162940

David B. Soll - Philadelphia PA
Sol E. Harrison - Huntingdon Valley PA

A61K 31715

514 54

The cells of the coverings and linings of internal human and animal tissues, organs and body cavities subject to trauma, such as surgery, may be protected against exfoliation or destruction by the topical application or injection of effective amounts of chondroitin sulfate prior to or during the trauma. Preferably, the chondroitin sulfate is used in physiological solutions in concentrations of about 40 to 55 weight percent, and may be used as a surgical irrigating solution. Intraarticular injection of such chrondroitin sulfate solutions into human and animal joints having degenerative joint conditions protects the joint cells, reduces aseptic inflammation and/or prevents further dengeration of cartilage tissue. Solutions for preserving human and animal cells and tissues in vitro for later in vivo use have extended storage life when chondroitin sulfate is added to such storage solutions in effective amounts such as about 1 to 20 weight percent of the storage solution.

5722762, Mar 3, 1998

Jul 18, 1996

8/683281

David B. Soll - Philadelphia PA

F21L 1514

362105

An illumination device for mounting on the head of a user including a frame having a cross member and a pair of rearwardly extending temple members attached to opposite ends of the cross member. At least one focusable light assembly is rotatably mounted to the frame and includes a light source for emitting light. The light assembly is adjustable by the user for varying the vergence and direction of the light emitted from the light source.

5715538, Feb 10, 1998

Sep 5, 1996

8/708522

David B. Soll - Philadelphia PA

A41D 2500

2145

A necktie securing device for securing to a shirt front a necktie having a tail, an apron and a label, the label being attached to a rear surface of the apron, to a shirt front when the tail is disposed within an opening formed by the label and the apron, includes a first clip demountably attachable to the tail and having a first VELCRO material covered joining surface and a second clip demountably attachable to an overlapping edge of the shirt front and having a second joining surface covered by complementary VELCRO material, the second joining surface of the second clip being engageable with the first joining surface of the first clip.